By multivariate analysis, in TN PLWH, 2-DR had a lower risk of discontinued treatment (hazard ratio [HR]: 0.23, 95% CI: 0.05 to 1.1, p = 0.07), adjusted by age, sex, rate of PLWH with HCV coinfection, CD4+ T-cell count (cells/μL) and Log VL at study treatment initiation. The gene discussed is CD4; the disease is coinfection.